GLP-1 Medications and Surgery: What the Pre-Op Conversation Should Cover

Why This Question Comes Up in the First Place

GLP-1 receptor agonists work partly by slowing gastric emptying — the rate at which your stomach moves food and liquid into the small intestine. That mechanism is unrelated to the reason you're having surgery, but it matters to an anesthesia team for a specific reason: sedation and general anesthesia suppress the reflexes that normally protect your airway if stomach contents come back up. If more food or liquid than expected is still sitting in the stomach at the time of the procedure, that raises the theoretical risk of regurgitation and aspiration — inhaling stomach contents into the lungs — during induction. This is the mechanism anesthesia and gastroenterology societies were responding to when they first raised concerns about GLP-1s in the perioperative period, and it's worth understanding the "why" before the "what," because it explains why the guidance is about timing and diet rather than about the medication being unsafe to take at all.

What the Current Multi-Society Guidance Actually Says

In October 2024, a joint group — the American Society of Anesthesiologists, the American Gastroenterological Association, the American Society for Metabolic and Bariatric Surgery, the International Society of Perioperative Care of Patients with Obesity, and the Society of American Gastrointestinal and Endoscopic Surgeons — published updated guidance in the journal Surgical Endoscopy. It explicitly replaced the earlier 2023 advice, which had leaned toward holding GLP-1 medications ahead of any procedure regardless of individual circumstances. The new guidance describes itself as guidance rather than an evidence-based guideline, because long-term perioperative outcome data on GLP-1s is still limited — but its core shift is clear: most patients can likely continue their GLP-1 medication before elective surgery, and the decision should be individualized rather than automatic.

The document frames this explicitly as a shared decision-making process involving the patient, the procedural team, the anesthesia team, and the prescribing clinician together — weighing the metabolic or weight-management benefit of staying on the medication against the aspiration-risk considerations for that specific patient and procedure. That framing matters logistically: it means there isn't a single answer you can look up and apply to yourself, and it means the conversation needs to happen with more than one person on your care team, not just your surgeon or just your prescriber.

How Your Care Team Might Assess Your Risk

The guidance identifies several factors that raise the concern about delayed gastric emptying at the time of a procedure. None of these are things you should use to diagnose your own risk level — they're listed here so you know what your care team may ask about:

• Escalation phase vs. maintenance phase. Patients still working up through dose increases are generally considered to carry more risk than patients who have been on a stable maintenance dose for a while.
• Weekly vs. daily formulation. Weekly injectable formulations stay active in the body longer than daily ones, which affects how far in advance a hold (if recommended) would need to start.
• Dose. Higher doses are generally associated with more pronounced effects on gastric emptying.
• Active GI symptoms. Ongoing nausea, vomiting, bloating, or abdominal pain going into a procedure is a flag, independent of dose or phase.
• Comorbid conditions. Conditions like gastroparesis, other causes of bowel dysmotility, or Parkinson's disease can independently slow gastric emptying and compound the effect.

Your surgical and anesthesia team will typically ask about these directly during pre-op screening — which is exactly why it helps to have thought through the answers (and your medication history) before you're asked.

What Happens If You're Considered Lower Risk

For patients without the risk factors above — stable on a maintenance dose, no active GI symptoms, no relevant comorbidities — the current guidance supports continuing the GLP-1 medication as usual leading into the procedure. That decision still belongs to your care team, not to a general article, but it's worth knowing going in that "continue normally" is a legitimate, guidance-supported outcome for many patients now, which wasn't the default position under the earlier 2023 advice.

What Happens If You're Considered Higher Risk

For patients flagged as higher risk, the guidance describes two tools care teams may use, separately or together:

• A defined hold. When a hold is recommended, the guidance describes holding daily formulations the day of the procedure, and holding weekly formulations roughly a week prior — reflecting how long each formulation stays active. Again, whether and how this applies to you is a decision made with your prescriber and surgical team, not a rule to apply to yourself.
• A preoperative clear-liquid diet. The guidance describes a clear-liquid diet for at least 24 hours before the procedure for higher-risk patients — the same kind of prep already used before colonoscopy or bariatric surgery — as a way to reduce retained stomach content independent of whether the medication itself is held.

Some anesthesia teams also use point-of-care gastric ultrasound on the day of the procedure to directly check for retained stomach contents when there's still uncertainty, and may adjust the anesthesia technique (for example, using rapid sequence induction) if retained contents are suspected or confirmed. None of this is something you arrange yourself — it's useful to know it exists so a same-day ultrasound or a change in anesthesia plan doesn't come as a surprise.

Getting This Onto Your Pre-Op Checklist

The most useful thing you can control here isn't a medical decision — it's making sure the right information reaches the right people early enough to act on it. A few practical steps:

• Raise it at scheduling, not at check-in. As soon as a procedure requiring sedation or anesthesia is scheduled, tell the scheduling staff you take a GLP-1 medication so it gets flagged in your chart, rather than mentioning it for the first time in a pre-op holding area.
• Tell your prescriber separately. The clinician managing your GLP-1 medication may not automatically know you have surgery scheduled unless you tell them — don't assume your surgeon's office and your GLP-1 prescriber's office are communicating with each other.
• Have your medication details ready. Exact drug name, dose, formulation (daily or weekly), and the date of your most recent dose — this is the information every team member will ask for, so write it down once and bring it to every appointment.
• Get any hold instructions in writing. If your team decides on a hold, ask for the specific date to stop and, separately, when it's appropriate to resume after the procedure — don't rely on memory for either.
• Ask about the liquid-diet instructions specifically if you're told you need one — what counts as a clear liquid varies by practice, and it's a different (usually stricter) list than typical pre-surgery fasting guidance.

Coordinating the Prescription Timeline Around a Hold

If your team recommends holding a weekly dose before your procedure, that creates a scheduling ripple effect worth planning for. Weekly GLP-1 prescriptions are typically filled on a set cadence tied to your regular injection day; skipping or delaying a dose for surgery can shift your next refill date out of sync with your pharmacy's and insurer's expectations. Before your procedure, it's worth a quick call to your pharmacy to flag that an upcoming fill may be delayed intentionally under a prescriber's instruction — this can prevent an automatic refill reminder or a "too soon to refill" rejection from causing confusion later. If your plan requires prior authorization on a recurring basis, see our guide on how insurance prior authorization works for how renewal timing interacts with gaps in your fill history.

If Your Surgery Falls During a Dose-Escalation Phase

Because escalation phase is one of the flagged risk factors, some patients with surgery scheduled during titration ask their prescriber whether to pause the escalation schedule and hold at a lower dose until after the procedure, rather than continuing to increase doses right up to surgery. This is a conversation for your prescriber, not a default recommendation — but it's a reasonable question to bring up if your procedure date happens to land during an active titration period. Our questions to ask before starting a GLP-1 guide has a broader framework for structuring these kinds of prescriber conversations if you haven't already been using one.

A Simple Pre-Op Checklist

• Confirm your procedure requires sedation or general anesthesia (not all do).
• Tell the scheduling office and your surgeon's intake team that you take a GLP-1 medication, including exact drug and dose.
• Separately notify your GLP-1 prescriber that you have a procedure scheduled.
• Ask your anesthesia team directly whether they want you to hold any doses, and if so, exactly which dates.
• Ask whether a clear-liquid diet is recommended for you, and get the specific list of what counts.
• Call your pharmacy if a hold will delay your next scheduled fill.
• Get all instructions in writing or repeated back to you before you leave the pre-op appointment.

Frequently Asked Questions

Do I have to stop my GLP-1 medication before surgery?

Not automatically. Current guidance moved away from a blanket hold toward a shared decision based on your specific risk factors, made with your surgical team, anesthesia provider, and prescriber together.

Why does this even come up?

GLP-1 medications slow gastric emptying, which can leave more stomach content than expected going into sedation — a factor anesthesia teams weigh against aspiration risk.

What makes someone "higher risk" in this context?

Being in a dose-escalation phase, using a weekly formulation, a higher dose, active GI symptoms, or comorbidities like gastroparesis are the factors the current guidance flags for care teams to weigh.

What is the liquid-diet recommendation about?

For higher-risk patients, a clear-liquid diet for at least 24 hours before the procedure — similar to colonoscopy prep — is one tool teams may use to reduce retained stomach content.

Who should know that I take a GLP-1 medication?

Your surgeon, anesthesia provider, pre-op nurse, and your GLP-1 prescriber should each have it documented — don't assume one office has told another.

Sources

• American Society of Anesthesiologists — New Multi-Society GLP-1 Guidance (October 2024)
• Surgical Endoscopy — Multi-Society Clinical Practice Guidance for the Safe Use of GLP-1 Receptor Agonists in the Perioperative Period
• FDA — Wegovy (semaglutide) Prescribing Information
• American Society of Anesthesiologists — Why GLP-1 Receptor Agonists Matter in the OR